Press "Enter" to skip to content

Overall Survival, Response Rate Improved With Triplet Regimen in BRAF-Mutant CRC – Targeted Oncology

admin 0

Overall Survival, Response Rate Improved With Triplet Regimen in BRAF-Mutant CRC  Targeted Oncology

The combination of encorafenib, binimetinib, and cetuximab reduced the risk of death by 48% in patients wtih BRAF V600E-mutant metastatic colorectal cancer …

“colorectal cancer” – Google News

(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *